



**Kidney Cancer Association™**

Unstoppable Together.

## **Kidney Cancer Association Advanced Discovery Award (ADA)**

**Purpose:** Advanced Discovery Awards promote collaboration between a clinician and a translational researcher to propose novel research that could lead to a significant advance in the treatment of people with kidney cancer. This may include biomarker development, development of novel therapeutic targets, correlative studies associated with ongoing or completed clinical trials, or assays that promote the early detection of kidney cancer. Proposals will be evaluated through a Letter of Intent (LOI) Process.

**Applicant:** Collaboration between a minimum of one clinician (MD, DO, or equivalent) and one translational researcher (Ph. D., M. D., D. O.) with at least one team member having an academic rank of Associate Professor or higher. The collaboration can be intra or inter institutional.

All application materials should be submitted electronically in PDF format, in English, via <https://kidneycancer.submittable.com/submit>

All questions regarding the grant application process should be submitted to [grants@kidneycancer.org](mailto:grants@kidneycancer.org).

**Funding:** \$500,000

Funding will be distributed in 50% allotments (\$250,000) for years 1 and 2. The second allotment is contingent on the successful submission of a progress report highlighting the accomplishments of the first year of work. The funding is to be used solely for research costs, with a maximum of 5% utilized for institutional indirect costs if necessary. The funding cannot be used for the investigator's salary support or things not directly related to the proposed research (i.e. travel, society memberships, etc.). The research award can be used to support the salaries of research personnel directly involved in the conduct of the research proposed.

### **Timeline for the Application and Granting Process:**

March 1, 2021:	Call for Letters of Intent
April 29, 2021:	Final Day to submit Letters of Intent
May 27, 2021:	Final Day that Meritorious LOI Proposals will be notified to proceed with preparation and submission of a full proposal for evaluation
July 15, 2021:	Final Day to submit Full Proposal for academic review
September 27, 2021:	The winning research teams will be notified and announced publicly
October 7, 2021:	Initial awards of \$250,000 distributed to award winners
October 7, 2022:	Progress Report on 1 <sup>st</sup> year of research progress due. If deemed meritorious, the second allotment of \$250,000 will be dispersed
October 7, 2023:	Final Progress Report Due

**Reviewers:** An independent panel of reviewers who are recognized experts in the field will be assembled to conduct a scored review of the letters of intent and the final proposals based on published NIH guidelines. This will include at least one pathologist, one geneticist, one urologist, and one medical



**KidneyCancerAssociation™**

Unstoppable Together.

oncologist, as well as patient advocates. Members with a conflict of interest on a given proposal will recuse themselves from the deliberation.

**Letters of Intent:** Applicants will submit a two-page, single-spaced, Arial 11 font proposal in PDF format for review, inclusive of graphs/charts. Applicants will submit both unredacted and redacted (hiding all identifying information) versions. The proposal should include the following sections:

- Background Summary
- Impact Summary
- Purpose/Objective of Study
- Brief Overview of Methods
- Lay Summary(200-word limit suggested)

**Accompanying Documentation:**

- Biosketches of collaborators, with contact information
- One paragraph personal statement from each researcher describing their background and commitment to kidney cancer research
- Relevant IRB-approved protocols for use of human or animal specimens in the proposed research
- Supporting documentation from a pharmaceutical company if a drug is proposed in the research plan
- Letter of support from each applicant's department or division chairperson

Applicants will be notified by email as to the status of their letter of intent by May 27, 2021.

**Full Proposals:** Meritorious applicants selected to submit a full proposal will submit < or equal to a 6 page, single-spaced, Arial font 11 document in PDF format. All relevant graphs, tables, and figures must be included within the 6 pages. The document should include:

- Background and work done to date
- Specific aims
- Methodology, including alternative methods should the primary plan go awry
- Potential impact on kidney cancer patient care
- Timelines and actionable goals of the research plan
- Budget and justification
- Cite relevant literature

Applicants should indicate whether or not their research proposal is under consideration by other granting mechanisms.

Proposals will be scored using the traditional NIH 1-9 system for:

- Significance
- Approach



**KidneyCancerAssociation™**  
Unstoppable Together.

- Innovation
- Environment
- Overall

Award winners will be notified by September 27, 2021, and initial funds will be dispersed by October 7, 2021.

Award recipients must complete periodic reports and submit their research to at least one accredited conference/meeting (i.e. IKCS, ASCO, etc). Recipients are also asked to notify the KCA about and acknowledge the award in publications or presentations that result from the research.